根据ESI于2024年9月发布的数据，我校高被引论文（Highly Cited Papers）484篇，热点论文（Hot Papers）18篇，见附件：2024年9月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在484篇高被引论文中，临床医学最多（239篇），占比49.38%，分子生物学与遗传学43篇（8.88%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2024.09 |
2024.07 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
1 |
CLINICAL MEDICINE |
239 |
49.38% |
225 |
49.02% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
43 |
8.88% |
41 |
8.93% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
37 |
7.64% |
34 |
7.41% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
36 |
7.44% |
32 |
6.97% |
|
5 |
MATERIALS SCIENCE |
33 |
6.82% |
31 |
6.75% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
14 |
2.89% |
17 |
3.70% |
|
7 |
ENGINEERING |
8 |
1.65% |
7 |
1.53% |
|
8 |
MICROBIOLOGY |
10 |
2.07% |
8 |
1.74% |
|
9 |
CHEMISTRY |
5 |
1.03% |
7 |
1.53% |
|
10 |
PHYSICS |
10 |
2.07% |
10 |
2.18% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
11 |
2.27% |
10 |
2.18% |
|
12 |
IMMUNOLOGY |
12 |
2.48% |
10 |
2.18% |
|
13 |
SOCIAL SCIENCES, GENERAL |
5 |
1.03% |
6 |
1.31% |
|
14 |
COMPUTER SCIENCE |
9 |
1.86% |
10 |
2.18% |
|
15 |
GEOSCIENCES |
1 |
0.21% |
1 |
0.22% |
|
16 |
AGRICULTURAL SCIENCES |
3 |
0.62% |
5 |
1.09% |
|
17 |
MULTIDISCIPLINARY |
1 |
0.21% |
1 |
0.22% |
|
18 |
ENVIRONMENT/ECOLOGY |
5 |
1.03% |
3 |
0.65% |
|
19 |
MATHEMATICS |
2 |
0.41% |
1 |
0.22% |
|
20 |
合计 |
484 |
100.00% |
459 |
100.00% |
|
序号 |
2024年9月我校18篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
TRIAL OF ENDOVASCULAR THERAPY FOR ACUTE ISCHEMIC STROKE WITH LARGE INFARCT |
NEW ENGLAND JOURNAL OF MEDICINE 388 (14): 1272-1283 APR 6 2023 |
10.1056/NEJMoa2213379 |
CLINICAL MEDICINE |
225 |
|
2 |
MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES |
JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024 |
10.1002/jev2.12404 |
BIOLOGY & BIOCHEMISTRY |
153 |
|
3 |
ASSOCIATION BETWEEN GUT MICROBIOTA AND PREECLAMPSIA-ECLAMPSIA: A TWO-SAMPLE MENDELIAN RANDOMIZATION STUDY |
BMC MEDICINE 20 (1): - NOV 15 2022 |
10.1186/s12916-022-02657-x |
CLINICAL MEDICINE |
148 |
|
4 |
ESTIMATED BURDEN OF STROKE IN CHINA IN 2020 |
JAMA NETWORK OPEN 6 (3): - MAR 2023 |
10.1001/jamanetworkopen.2023.1455 |
CLINICAL MEDICINE |
132 |
|
5 |
OVERALL SURVIVAL WITH OSIMERTINIB IN RESECTED <I>EGFR</I>-MUTATED NSCLC |
NEW ENGLAND JOURNAL OF MEDICINE 389 (2): 137-147 JUL 13 2023 |
10.1056/NEJMoa2304594 |
CLINICAL MEDICINE |
108 |
|
6 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
99 |
|
7 |
REPRESSION OF THE ANTIPORTER SLC7A11/GLUTATHIONE/GLUTATHIONE PEROXIDASE 4 AXIS DRIVES FERROPTOSIS OF VASCULAR SMOOTH MUSCLE CELLS TO FACILITATE VASCULAR CALCIFICATION |
KIDNEY INTERNATIONAL 102 (6): 1259-1275 DEC 2022 |
10.1016/j.kint.2022.07.034 |
CLINICAL MEDICINE |
92 |
|
8 |
SYNERGISTIC REINFORCING OF IMMUNOGENIC CELL DEATH AND TRANSFORMING TUMOR-ASSOCIATED MACROPHAGES VIA A MULTIFUNCTIONAL CASCADE BIOREACTOR FOR OPTIMIZING CANCER IMMUNOTHERAPY |
ADVANCED MATERIALS 34 (51): - DEC 2022 |
10.1002/adma.202207593 |
MATERIALS SCIENCE |
76 |
|
9 |
BIOMARKERS OF AGING |
SCIENCE CHINA-LIFE SCIENCES : - APR 11 2023 |
10.1007/s11427-023-2305-0 |
BIOLOGY & BIOCHEMISTRY |
73 |
|
10 |
MICRO- AND NANOPLASTICS: A NEW CARDIOVASCULAR RISK FACTOR? |
ENVIRONMENT INTERNATIONAL 171: - JAN 2023 |
10.1016/j.envint.2022.107662 |
ENVIRONMENT/ECOLOGY |
53 |
|
11 |
CRISPR-CAS13A-POWERED ELECTROCHEMICAL BIOSENSOR FOR THE DETECTION OF THE L452R MUTATION IN CLINICAL SAMPLES OF SARS-COV-2 VARIANTS |
JOURNAL OF NANOBIOTECHNOLOGY 21 (1): - APR 29 2023 |
10.1186/s12951-023-01903-5 |
BIOLOGY & BIOCHEMISTRY |
52 |
|
12 |
CURRENT THERAPY AND DRUG RESISTANCE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
DRUG RESISTANCE UPDATES 68: - MAY 2023 |
10.1016/j.drup.2023.100962 |
PHARMACOLOGY & TOXICOLOGY |
43 |
|
13 |
LIBERATION OF DAIDZEIN BY GUT MICROBIAL Β -GALACTOSIDASE SUPPRESSES ACETAMINOPHEN-INDUCED HEPATOTOXICITY IN MICE |
CELL HOST & MICROBE 31 (5): 766-+ MAY 10 2023 |
10.1016/j.chom.2023.04.002 |
MICROBIOLOGY |
28 |
|
14 |
HERTHENA-LUNG01, A PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED NON-SMALL-CELL LUNG CANCER AFTER EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND PLATINUM-BASED CHEMOTHERAPY |
JOURNAL OF CLINICAL ONCOLOGY 41 (35): 5363-+ DEC 10 2023 |
10.1200/JCO.23.01476 |
CLINICAL MEDICINE |
24 |
|
15 |
PHOTOTHERMAL THERAPY OF TUBERCULOSIS USING TARGETING PRE-ACTIVATED MACROPHAGE MEMBRANE-COATED NANOPARTICLES |
NATURE NANOTECHNOLOGY 19 (6): - JUN 2024 |
10.1038/s41565-024-01618-0 |
MATERIALS SCIENCE |
17 |
|
16 |
A RATIONALLY DESIGNED NUCLEI-TARGETING FAPI 04-BASED MOLECULAR PROBE WITH ENHANCED TUMOR UPTAKE FOR PET/CT AND FLUORESCENCE IMAGING |
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 51 (6): 1593-1604 MAY 2024 |
10.1007/s00259-024-06691-0 |
CLINICAL MEDICINE |
10 |
|
17 |
ENHANCED THE STABILITY AND STORAGE CAPABILITY OF SULFIDE-BASED MATERIAL WITH THE INCORPORATION OF CARBON NANOTUBE FOR HIGH-PERFORMANCE SUPERCAPATTERY DEVICE |
JOURNAL OF ELECTROCHEMICAL ENERGY CONVERSION AND STORAGE 21 (2): - MAY 1 2024 |
10.1115/1.4062642 |
ENGINEERING |
8 |
|
18 |
ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER |
NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024 |
10.1056/NEJMoa2310532 |
CLINICAL MEDICINE |
8 |
